NO20031070D0 - Antistoff og/eller kjemokinkonstrukter og deres anvendelse ved immunologiske forstyrrelser - Google Patents

Antistoff og/eller kjemokinkonstrukter og deres anvendelse ved immunologiske forstyrrelser

Info

Publication number
NO20031070D0
NO20031070D0 NO20031070A NO20031070A NO20031070D0 NO 20031070 D0 NO20031070 D0 NO 20031070D0 NO 20031070 A NO20031070 A NO 20031070A NO 20031070 A NO20031070 A NO 20031070A NO 20031070 D0 NO20031070 D0 NO 20031070D0
Authority
NO
Norway
Prior art keywords
antibody
immunological disorders
chemokine constructs
chemokine
constructs
Prior art date
Application number
NO20031070A
Other languages
English (en)
Other versions
NO20031070L (no
Inventor
Matthias Mack
Detlef Schloendorff
Michael Spring
Original Assignee
Micromet Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/948,004 external-priority patent/US6723538B2/en
Application filed by Micromet Ag filed Critical Micromet Ag
Publication of NO20031070D0 publication Critical patent/NO20031070D0/no
Publication of NO20031070L publication Critical patent/NO20031070L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
NO20031070A 2000-09-08 2003-03-07 Antistoff og/eller kjemokinkonstrukter og deres anvendelse ved immunologiske forstyrrelser NO20031070L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00119694 2000-09-08
US09/948,004 US6723538B2 (en) 1999-03-11 2001-09-05 Bispecific antibody and chemokine receptor constructs
PCT/EP2001/010433 WO2002020615A2 (en) 2000-09-08 2001-09-10 Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders

Publications (2)

Publication Number Publication Date
NO20031070D0 true NO20031070D0 (no) 2003-03-07
NO20031070L NO20031070L (no) 2003-05-06

Family

ID=32842663

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031070A NO20031070L (no) 2000-09-08 2003-03-07 Antistoff og/eller kjemokinkonstrukter og deres anvendelse ved immunologiske forstyrrelser

Country Status (10)

Country Link
EP (1) EP1317284A2 (no)
JP (1) JP2004508036A (no)
AU (1) AU2002212225A1 (no)
CA (1) CA2421842A1 (no)
HU (1) HUP0300942A2 (no)
NO (1) NO20031070L (no)
PL (1) PL366062A1 (no)
RU (1) RU2252786C2 (no)
WO (1) WO2002020615A2 (no)
ZA (1) ZA200301890B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002360073A1 (en) * 2001-12-21 2003-07-09 Micromet Ag Mono-and dual chemokine/cytokine constructs
EP2336179A1 (en) 2002-11-08 2011-06-22 Ablynx N.V. Stabilized single domain antibodies
EP1937311A2 (en) 2005-09-30 2008-07-02 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Methods and compositions for modulating immune tolerance
NZ575163A (en) 2006-08-28 2011-12-22 Jolla Inst Allergy Immunolog Antagonistic human light-specific human monoclonal antibodies
AR065369A1 (es) 2007-02-19 2009-06-03 Novartis Ag Derivados de ciclohexil - amida del acido aril- carboxilico
SG10201407388XA (en) 2007-08-29 2015-01-29 Sanofi Aventis Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
DK2585089T3 (en) * 2010-06-28 2016-12-12 Universitätsklinikum Freiburg CCL18 blockade of signaling through CCR6 as a therapeutic option in fibrotic diseases and cancer
EP4303236A3 (en) 2010-11-30 2024-03-20 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
CA2943943C (en) 2014-04-07 2023-01-10 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
SG11201609370QA (en) 2014-05-13 2016-12-29 Chugai Pharmaceutical Co Ltd T cell-redirected antigen-binding molecule for cells having immunosuppression function
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
US11649293B2 (en) 2015-11-18 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
WO2017210749A1 (en) * 2016-06-10 2017-12-14 Adelaide Research & Innovation Pty Ltd Methods and products for treating autoimmune diseases
CN109970856B (zh) 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
EP4090348A4 (en) * 2020-01-13 2024-05-15 The Regents of The University of California METHODS FOR TREATING VIRAL INFECTIONS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004926A2 (en) * 1998-07-22 2000-02-03 Osprey Pharmaceuticals Limited Conjugates for treating inflammatory disorders and associated tissue damage
ATE286074T1 (de) * 1999-03-11 2005-01-15 Micromet Ag Gegen ccr5 gerichtete antikörperkonstrukte und ihre verwendung in der behandlung von autoimmunkrankheiten

Also Published As

Publication number Publication date
ZA200301890B (en) 2004-03-16
EP1317284A2 (en) 2003-06-11
NO20031070L (no) 2003-05-06
WO2002020615A3 (en) 2002-07-25
JP2004508036A (ja) 2004-03-18
CA2421842A1 (en) 2002-03-14
RU2252786C2 (ru) 2005-05-27
HUP0300942A2 (hu) 2003-09-29
WO2002020615A2 (en) 2002-03-14
AU2002212225A1 (en) 2002-03-22
PL366062A1 (en) 2005-01-24

Similar Documents

Publication Publication Date Title
NO20031070D0 (no) Antistoff og/eller kjemokinkonstrukter og deres anvendelse ved immunologiske forstyrrelser
NO20010576D0 (no) Immunologiske herpes simplex-virusantigener og fremgangsmåte for anvendelse derav
DK1163271T3 (da) Rekombinant IL-18 antistoffer og deres anvendelse
DK2325317T3 (da) Receptornukleinsyrer og polypeptidr
NO20034405L (no) Anti-ostepontin-antistoff og anvendelse derav
HRP20030342A2 (en) Bridge deck panels, fabrication methods and use
NO20023788L (no) Antistoff som binder humant interleukin-18 samt fremgangsmater ved fremstilling og anvendelse derav
NO20040364L (no) Tienopyrimidindioner og deres anvendelse ved modulering av autoimmune sykdommer
NO20030111D0 (no) Kjemokinreseptor-modulatorer, deres fremstilling og anvendelse
DK1023241T3 (da) Kolloide borsilikater og deres anvendelse i produktion af papir
IL151853A (en) Multivalent antibodies and uses thereof
NO20020554L (no) Antistoff-molekyler med spesifisitet for human tumornekrosefaktor-alfa, og anvendelse derav
EP1470159A4 (en) ANTIBODIES AGAINST LATENT MEMBRANE PROTEINS (LMP) AND USES THEREOF
IL201889A0 (en) Antibody recognizing nkt cells and uses thereof in the treatment of immune-related disorders
DE60138457D1 (de) Gleichlaufgelenk mit feststehendem zentrum und sich kreuzenden rillen
SM200000032B (it) Pannello modulare per la realizzazione di edifici in genere, con caratteristiche di isolamento termico ed acustico
DK1328475T3 (da) Zeolitter og deres anvendelse
ITWX20020001A1 (it) Perfezionamenti in e relativi al lancio dei missili.
NO20031701D0 (no) Fremgangsmåte og mellomprodukter i fremstilling av 7- substituerte antiöstrogener
NO20030882L (no) Glasskeramikkmasse og anvendelse derav
FR2833610B1 (fr) Construits cellulaires cultives in vitro, preparation et utilisations
DK1276762T3 (da) Rekombinante porphyromonas gingivalis-proteiner og trunkeringer
NO20033415D0 (no) Alkoksylerte polyglyceroler og deres anvendelse som demulgeringsmidler
NO20014946L (no) Strukturerte multiformåls-pakkinger og deres anvendelse
EP1452587A4 (en) STEM CELLS DERIVED FROM STORM DUETTEPLITHELZELLES AND USE THEREOF

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application